Lamotrigine Tablet
Product Images NDC 43063-238

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 43063-238). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063238 Label (43063238)

Label for LAMOTRIGINE USP 25 mg oral tablets by PD-Rx Pharmaceuticals, Inc. The label indicates a 30-tablet package with NDC 43063-238-30. It includes reorder number 103317, lot number L19B52, and expiration date 12/2021, as well as a black box highlighting the 25 mg strength. The label features warning to keep out of reach of children and advises consulting a doctor for side effects.*

FDA Label Image

5a15187f B147 4147 A4ef 0e3e5de73cb6 01

Chemical structure of lamotrigine, showing a chlorinated phenyl ring attached to a triazine ring with amino groups. The chlorines are positioned on the phenyl ring, and the triazine includes nitrogen atoms and an amino group, representing the molecular structure of the active ingredient lamotrigine.*

FDA Label Image

5a15187f B147 4147 A4ef 0e3e5de73cb6 02

A survival curve chart showing failure probability (%) on the vertical axis and weeks on the horizontal axis over a 100-week period, comparing Placebo and Lamotrigine groups. The graph includes censored data points marked with crosses and indicates higher failure probability for Placebo compared to Lamotrigine across weeks.*

FDA Label Image

5a15187f B147 4147 A4ef 0e3e5de73cb6 03

A Kaplan-Meier failure probability curve comparing Lamotrigine and Placebo over a span of approximately 80 weeks. The y-axis shows failure probability percentage from 0 to 100%, and the x-axis represents time in weeks. The graph includes censored data points and shows that Lamotrigine maintains a lower failure probability than Placebo throughout most of the period.*

FDA Label Image

708290c4 B959 47cc 95a1 38a6270297e5 1119 2

Dimensional drawings of lamotrigine tablets showing the imprint and shape on the upper and lower faces for strengths 25 mg, 100 mg, 150 mg, and 200 mg. Each tablet strength has distinct imprints and scored lines on the lower face.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.